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Abstract 
Introduction: Sleep disorders are among the most common non-motor symptoms in patients with 
cervical dystonia (CD), Parkinson's disease (PD), and depression. The study aimed to assess the 
prevalence and characteristics of sleep disorders in patients with cervical dystonia compared to 
healthy controls, patients with Parkinson's disease, and patients with depression. 
Methods: In this cross-sectional study, we evaluated 122 patients (30 control patients, 30 with cervical 
dystonia, 32 with Parkinson's disease, and 30 with depression). Demographic data were collected. All 
of them, except for the depression group, were tested for depression and anxiety using the Beck 
Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). Sleep disorders were evaluated using 
the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS). Statistical significance 
was defined at α=0.05. 
Results: Patients with cervical dystonia differed from the healthy control group in terms of PSQI score 
and some subscales. The depression group differed in most PSQI subscales when compared to the 
patients with Parkinson's disease and cervical dystonia, while the latter two groups of patients 
differed only in the duration subscale. Patients with Parkinson's disease differed from other groups 
of patients only in one subscale - daytime sleepiness. 
Conclusion: Cervical dystonia patients suffer from more sleep disturbances when compared to 
healthy controls. There are differences in the frequency and extent of sleep disturbances with less 
pronounced symptoms in patients with cervical dystonia and Parkinson's disease, while patients with 
depression present the most pronounced symptoms. Symptoms of depression and anxiety correlate 
with sleep disturbances in patients with Parkinson's disease and cervical dystonia. Patients with 
cervical dystonia do not experience daytime sleepiness problems. 
(Tomic S, Degmecic D, Gjoni F, Dumencic I, Milanovic S, Gilman Kuric T, Popovic Z, Mirosevic Zubonja 
T. Sleep Disorders in Cervical Dystonia, Parkinson’s Disease and Depression – What is the Difference? 
SEEMEDJ 2020; 4(2); 35-47) 
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Introduction 
Circadian rhythm can be defined as changes in 
biological and behavioural conditions between 
the states of high and low activity during 24 
hours. It is regulated by two paired nuclei 
located in the hypothalamus, called the 
suprachiasmatic nucleus (SCN). The process 
starts with retinal light stimulation that generates 
a signal through the retinohypothalamic tract to 
the SCN, which then generates a signal that 
stimulates the pineal gland. The process of 
stimulation involves a multi-synaptic link 
through the superior cervical ganglion, which 
releases noradrenaline during the night, 
inducing the activity of the serotonin-N-
acetyltransferase (SNAT) enzyme via cyclic 
adenosine monophosphate (cAMP). This 
stimulates the pineal gland to produce the 
hormone melatonin during the night and release 
it into the circulation to facilitate sleep [1]. The 
neurotransmitters that are important in the 
process of wakefulness are serotonin, 
noradrenaline, and acetylcholine, and they are 
released by the neurons located in the 
ventrolateral preoptic nucleus [2]. Introduction to 
the rapid-eye-movement (REM) phase of sleep 
is characterized by a decrease in 
monoaminergic (serotonin, norepinephrine, and 
dopamine) tone with a parallel increase in 
cholinergic tone [3]. In non-REM sleep, 
glutamate signalling is important during 
thalamocortical slow oscillations [4]. The 
secretion of the hormone cortisol is decreased 
during normal deep sleep and 
hypercortisolaemia can induce insomnia [5]. 
Sleep disorders could be classified into several 
types: delayed sleep phase syndrome (DSPS), 
advanced sleep phase syndrome (ASPS), 
irregular sleep-wake pattern, and non-24-hour 
sleep-wake syndrome in blind and sighted 
persons. Delayed sleep phase syndrome is a 
sleep disorder where the patient has problems 
falling asleep and waking up at conventional 
times, and the assumption is that the 
pathophysiological basis lies in delayed 
endogenous melatonin secretion [6]. Advanced 
sleep phase syndrome is characterized by 
persistent early evening sleep onset and early 
morning awakening with no sleep-maintenance 
problems. It is an age-related problem, the 
pathophysiology of which is as a consequence 
of diminution in the output of the circadian 
pacemaker [7]. The syndrome of an irregular 
sleep-wake pattern is characterized by 
temporally disorganized and variable episodes 
of sleeping and waking behaviour. 
Focal dystonia is characterized by sustained or 
intermittent muscle contraction causing 
abnormal, often repetitive movement, posture, 
or both. Cervical dystonia (CD) is a focal dystonia 
type where neck muscles are involved [8]. The 
aetiology of CD is still unknown. Recent articles 
suggest miscommunication between the basal 
ganglia and cerebellar loops [9]. In CD, besides 
typical motor symptoms, patients also 
experience non-motor symptoms, such as 
depression, anxiety, cognitive decline, pain, and 
sleep disorders [10,11]. The aetiology of sleep 
disorders in this patient group remains 
unresolved. There is no evidence that it is related 
to motor symptoms or that the relief from 
botulinum toxin treatment used for motor 
symptoms does not improve sleep disorders 
[12]. Video-polysomnographic recordings in CD 
patients showed that the activity over cervical 
muscles disappeared during all sleep stages 
and thus could not influence sleep impairment 
[13]. One of the theories is that sleep disturbance 
is related to the dysfunction of some brain 
regions, such as the basal ganglia, with 
dopaminergic system disturbance. Another 
theory is that it is related to depression [14]. 
Parkinson's disease (PD) is a neurodegenerative 
disorder with alpha-synuclein inclusions as the 
main hallmark of disease pathology. During the 
disease course, α-synuclein pathology spreads 
from the brain stem to higher cortical regions, 
with consequential neuron degeneration. As a 
result of degeneration, there is a loss of many 
neurotransmitters in the brain, such as 
dopamine, serotonin, noradrenaline, and 
acetylcholine. This causes many motor and non-
motor symptoms, including sleep disorders, 
among many other non-motor symptoms 
described [15]. Multiple factors could influence 
sleep disturbances, such as age-related 
SEEMEDJ 2020, VOL 4, NO. 2 Sleep Disorders in Neurological Diseases 
37 Southeastern European Medical Journal, 2020; 4(2) 
 
changes in sleep, nocturnal motor symptoms 
(rigidity, resting tremor, akinesia, tardive 
dyskinesia, and the ‘wearing-off’ phenomenon), 
non-motor symptoms (pain, hallucination, and 
psychosis), nocturia, and medication. Besides 
that, as part of PD pathology, there are changes 
in the neurotransmitter systems (dopamine, 
norepinephrine, serotonin, and acetylcholine) 
responsible for regulating sleep structure and 
the sleep/wake cycle [16]. 
Major depressive episodes are characterized by 
a period of depressed mood or anhedonia 
lasting for 2 or more weeks, with at least three 
additional signs, i.e. weight change or change in 
appetite, psychomotor agitation or retardation, 
feeling of worthlessness or guilt, diminished 
ability to concentrate, suicidal ideations or 
attempts, and insomnia or hypersomnia. 
Changes in neurotransmitter levels, such as a 
decrease of serotonin, norepinephrine and 
dopamine, and hypercortisolaemia are possible 
aetiologic factors of depression. Sleep 
disturbance is one of the most consistent 
symptoms. It can precede the symptoms of 
depression or persist after the disease remission 
and it is not related to depression itself. There 
are several theories on the aetiology of sleep 
disturbance in depression. One of them refers to 
monoaminergic level disruption, another one to 
glutamate level decrease, and one to 
hypercortisolaemia. However, none of them 
includes a clear conclusion regarding its 
aetiology [4].  
The aim of the study was to assess the 
prevalence and characteristics of sleep 
disorders in patients with cervical dystonia, 
compared to healthy controls, patients with 
Parkinson's disease, and patients with 
depression. 
Subjects and Methods  
In this cross-sectional study, we analysed 122 
subjects, 30 of whom were healthy controls, 30 
CD patients, 32 PD patients, and 30 were 
subjects diagnosed with depression. The study 
was conducted at the Department of Neurology 
and Department of Psychiatry, University 
Hospital Centre Osijek, from February to May 
2017. All the participants signed a written 
informed consent. The study protocol was 
reviewed and approved by the University 
Hospital Centre Osijek Ethics Board and it was in 
accordance with the Declaration of Helsinki. CD 
patients were recruited from the botulinum toxin 
clinic and tested during their regular follow-up 
examinations (without relation to their botulinum 
injections schedule). The control group included 
sex- and age-matched healthy relatives and 
friends of CD patients. PD patients were 
recruited from the movement disorders clinic. 
PD diagnosis was made according to the UK PD 
Society Brain Bank (UKPDSBB) diagnostic 
criteria and both early and advanced PD patients 
were analysed [17]. Depressed patients were 
recruited from the psychiatric ward where they 
were hospitalized due to depression problems. 
Control, PD, and CD groups were tested for 
symptoms of depression and anxiety by using 
the Beck Depression Inventory (BDI) and Beck 
Anxiety Inventory (BAI). Severity of depression 
and anxiety were not evaluated in depressed 
patients. All patients were tested for sleep 
disturbances using the Pittsburgh Sleep Quality 
Index (PSQI) for night-time disturbances and 
Epworth Sleepiness Scale (ESS) for daytime 
sleepiness problems. The PSQI has been 
designed to assess sleep quality and 
disturbances over a 1-month time interval. It is a 
self-rated questionnaire that can be filled in 10-
15 minutes. There are 19 individual questions 
divided into 7 subscales assessing subjective 
sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, 
use of sleeping medication, and daytime 
dysfunction. The sum of all 7 subscales provides 
the global PSQI score ranging from 0 to 21, 
where lower scores denote better sleep quality 
[18]. The ESS is a simple self-administered 
questionnaire designed to measure daytime 
sleepiness. It consists of 8 questions about how 
likely would it be for the subject to doze off in 8 
different situations (sitting and reading; watching 
TV; sitting, inactive, in a public place; as a 
passenger in a car for an hour without a break; 
lying down to rest in the afternoon; sitting and 
talking to someone; sitting quietly after lunch 
without alcohol; and, in a car, while stopped for 
SEEMEDJ 2020, VOL 4, NO. 2 Sleep Disorders in Neurological Diseases 
38 Southeastern European Medical Journal, 2020; 4(2) 
 
a few minutes in the traffic). After scoring every 
situation on a scale from 0 (would never doze 
off) to 3 (high chance to doze off), the total sum 
is calculated. The maximum score is 24. The 
score is higher in patients having more problems 
with daytime sleepiness [19]. A demographic 
questionnaire was designed for the study. All 
procedures performed in studies involving 
human participants were in accordance with the 
ethical standards of the institutional and/or 
national research committee and with the 1964 
Helsinki declaration and its later amendments or 
comparable ethical standards. Study was 
approved in 2016 by local Ethical Committee of 
Medical school in University of J. J. Strossmayer 
in Osijek.  Informed consent was obtained from 
all individual participants included in the study. 
Statistical analysis 
Categorical data were expressed as absolute 
frequencies and percentages, while the 
differences between the groups were tested by 
Fisher’s exact test. Numerical data were 
expressed as median and interquartile ranges or 
as mean and standard deviations, depending on 
whether the data indicated normal distribution, 
which was tested by the Kolmogorov-Smirnov 
test. Correlation between variables that did not 
indicate normal distribution was tested with 
Spearman's rank correlation coefficient. 
Differences between the groups in which the 
data did not indicate normal distribution were 
tested by the Kruskal-Wallis test. Statistical 
significance was defined as α=0.05. Post hoc 
analysis of differences between the two groups 
was done with the Mann-Whitney U test and, 
after the Bonferroni correction, statistical 
significance was defined as P<0.016. Statistical 
analysis was conducted by using STATISTICA 13 
(StatSoft Inc., Tulsa, Oklahoma, USA). 
Results 
There were differences among the patient 
groups in terms of age (PD patients were older 
than subjects from other groups), while the 
study groups were quite homogeneous in terms 
of sex (Table 1). There was no difference in 
disease duration among the three groups of 




Table 1 Demographic data regarding sex and age 
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Table 2 Differences in disease duration, symptoms of depression and anxiety between groups 
























































BDI – Beck Depression Inventory; BAI – Beck Anxiety Inventory; †Kruskal-Wallis test  
Post hoc analysis performed between groups by applying the Mann-Whitney U test indicated to the following significant 
differences: BDI between control and PD group (P < 0.008); BAI between control and PD group (P < 0.006).
There were significant differences in BDI and BAI 
scores between control, PD, and CD groups (BDI 
p<0.020 and BAI p<0.021). The post hoc analysis 
conducted between the groups by using the 
Mann-Whitney U test and the Bonferroni 
correction indicated a significant difference in 
BDI and BAI only between the PD and the control 
group (Table 2). A positive correlation between 
the BDI and PSQI scores in both patient groups 
(CD group rs 0.409, p<0.025; PD group rs 0.668, 
p<0.001) was found, but not between BDI and 
ESS (CD group rs 0.191, p<0.312; PD group rs 
0.093, p<0.612). When correlating BAI and PSQI, 
positive correlations both for PD and CD groups 
(PD group rs 0.604, p<0.001; CD group rs 0.370, 
p<0.044) was found, whereas for BAI and ESS a 
positive correlation only for the CD group was 
found (CD group rs 0.393, p<0.032; PD group rs 
0.271, p<0.133). The frequency of severity in the 
PSQI scale, ESS, and PSQI subjective score are 
shown in Table 3. 
Table 3 Frequency of severity of sleep disorders and subjective assessment between groups 





 N/% N/% N/% N/% P 
ESS 
 lower normal DS 
 higher normal DS 
 mild excessive DS 
 moderate excessive 
DS 


















































 very good 
 fairly good 
 fairly bad 


























DS – daytime sleepiness; ESS – Epworth Sleepiness Scale; PSQI – Pittsburgh Sleep Quality Index; * Fisher’s Exact Test 
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Post hoc analysis showed the following differences between the groups: control and CD (PSQI score P < 0.001); PD and 
CD (ESS score P < 0.017); PD and depression (PSQI score P < 0.007); CD and depression (PSQI score P < 0.001; subjective 
PSQI P < 0.042) 
 
We found significant differences among the 
groups for both scales and subjective PSQI 
scores. Post hoc analysis showed differences 
between the two groups (Table 3). Table 4 
shows PSQI subscale scores, while Figure 1 
shows global PSQI scores for the groups.  
Table 4 Differences in PSQI subscale scores between healthy control, Parkinson disease (PD), focal 
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PSQI – Pittsburgh Sleep Quality Index; †Kruskal-Wallis test 
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Post hoc analysis of differences between two groups carried out by applying the Mann-Whitney U test yielded significant 
differences for this subscale, and they are as follows: control and CD (P<0.001); PD and depression (P<0.001); CD and 
depression (P<0.001); duration score between control and CD (P<0.001); PD and CD (P<0.001); CD and depression 
(P<0.001); disturbance score between PD and depression (P<0.001); snoring score between CD and depression 
(P<0.009); nightmare score between control and CD (P<0.004); CD and depression (P<0.003); pain score between 
control and CD (P<0.001); other score between PD and depression (P<0.001); CD and depression (P<0.001); hypnotics 
usage score between PD and depression (P<0.001); CD and depression (P<0.001); dysfunctionality score PD and 
depression (P<0.006); CD and depression (P<0.001); enthusiasm score between PD and depression (P<0.001); CD and 
depression (P<0.001). 
 
The median score did not differ between some 
groups, but the interquartile range indicated to 
differences among them. Significant differences 
among the groups in terms of global scores 
were observed (Figure 1), but also with regard to 
many subscales. Post hoc analysis, following the 
application of the Bonferroni correction, showed 
differences between the two groups (Table 4).  
Figure 1 Global PSQI score between groups 
 
PSQI – Pittsburgh Sleep Quality Index.   
Post hoc analysis consisting of the Mann-Whitney U test, caried out after Bonferroni correction in order to determine 
differences between two groups: PSQI score between control and CD groups (P < 0.004); PD and depression groups (P 
< 0.001); and CD and depression groups (P < 0.001). 
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Table 5 shows results pertaining to ESS subscale 
scores, while Figure 2 shows total ESS scores for 
all the groups. There were no significant 
differences in total ESS scores between the CD 
and control group, or between patient groups 
(after Bonferroni correction) (Figure 2).  Only the 
subscale “sitting in a public place” presented 
lower results in the PD group when compared to 
CD and depression groups (Table 5). 
Table 5 Differences in ESS subscale scores in between healthy control, Parkinson disease, focal 
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ESS – Epworth Sleepiness Scale; †Kruskal-Wallis test 
Post hoc analysis of differences between two groups carried out by applying the Mann-Whitney U test, which after 
applying the Bonferroni correction (P<0.016) yielded significant differences for this subscale, and they are as follows: 
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Figure 2 Total ESS scores between groups 
 
ESS – Epworth Sleepiness Scale.  
Post hoc analysis consisting of the Mann-Whitney U test that was performed to determine the differences between two 
patient groups showed the following differences: ESS score for PD and CD groups (P < 0.031). 
 
Discussion 
Patients with CD were analysed for sleep 
disturbance relative to the control group, and all 
three patient groups were analysed for sleep 
disturbances relative to each other. When 
compared to the control group, CD patients 
displayed more frequent sleep problems that 
included higher PSQI scores. However, there 
was no difference with regard to daytime 
sleepiness problems. They have reported longer 
latency to fall asleep, lower duration of sleep 
during the night, more frequent nightmares, and 
more pain that disturbed their night-time sleep. 
Avanzino et al. reported impairment in sleep 
duration, latency, and efficiency of sleep in 
patients with blepharospasm, but not in the CD 
patient group. Likewise, Antelmi et al. also found 
decreased sleep efficiency and increased sleep 
latency in video-polysomnographic recordings 
of CD patients [13,20]. Impairment in sleep 
latency has its pathophysiological basis in 
delayed endogenous melatonin secretion, 
probably due to lower noradrenaline and 
serotonin levels that are an important part of this 
process [1]. 
Although all three patient groups suffered from 
sleep disturbances, we still found differences 
among them. Sleep of PD patients during the 
night is of shorter duration when compared to 
the CD group. PD group was older than the CD 
group, so this difference could be related to age, 
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i.e. it could be a consequence of age-related 
diminution in the output of the circadian 
pacemaker [7]. The depression group differed 
from the CD group in terms of PSQI scores and 
most subscales. They reported prolonged 
latency, shorter duration of sleep, and worse 
quality of sleep resulting from snoring and 
nightmares. They also use hypnotics more often 
and are more likely to suffer from 
dysfunctionality and loss of enthusiasm during 
the day arising from their sleep problems. The 
depression group reported more of such similar 
problems when compared to the PD group 
(latency, duration of sleep, disturbances, and 
other problems and disturbances). They also 
used hypnotics more often and reported 
dysfunctionality and loss of enthusiasm during 
the day arising from their sleep problems. So, of 
the three patient groups, sleep problems were 
most pronounced in the depression group, 
followed by PD, and finally the CD group. Smit et 
al. published a paper about altered presynaptic 
serotonin transporter (SERT) binding in CD 
patients. They found that sleep disturbances 
were strongly linked to SERT binding in the 
raphe nuclei in CD patients [21]. Depression and 
anxiety in CD patients are related to serotonergic 
system impairment. Patients with CD 
accompanied by depression and anxiety 
present lower SERT (serotonin transport) binding 
in the midbrain/diencephalon [22]. We found 
that both anxiety and depression symptoms 
correlate with sleep disturbances in the CD 
group. This indicates that neurotransmitter 
impairment leading to depression and anxiety 
could be the aetiological factor of sleep 
disturbances in the CD group.  
All three patient groups had problems with 
waking up and there was no significant 
difference among them. Dopamine-containing 
neurons are involved in the regulation of the 
waking process [23]. There is evidence that the 
dopaminergic system is disturbed in CD patients 
with depression. Zoons et al. found alterations of 
striatal DAT (dopaminergic transport) and D2/3 
receptor binding in CD patients with depression 
[24]. In addition to dopamine, noradrenaline and 
acetylcholine are also important in the waking 
process. Noradrenaline levels are high during 
the waking state and low during sleep [25]. 
Noradrenergic and cholinergic cells in the pons 
increase firing to activate the waking pattern 
[26,27]. There is a case report about pathologic 
findings from an autopsy of a patient with 
primary segmental dystonia (Meige syndrome). 
The authors found moderate-to-severe 
neuronal loss in several brainstem nuclei, 
including the substantia nigra pars compacta, 
locus coeruleus, raphe nuclei, and 
pedunculopontine nucleus [28]. Another paper 
with histopathologic findings in CD patients did 
not report a neuronal loss in the 
pedunculopontine region, but described a 
pedunculopontine nucleus choline 
acetyltransferase deficiency with a functional 
cholinergic deficit [29]. This could explain the 
lower noradrenaline and acetylcholine levels in 
CD patients, which are an important part of the 
wake-sleep cycle. 
There was no difference in ESS scores between 
the CD and control group, but the PD group 
reported lower ESS scores more frequently 
when compared to the CD patient group. In 
terms of subscales, and after the Bonferroni 
correction, a significant difference was found 
only with regard to the risk of falling asleep while 
sitting in public, where PD patients reported 
higher chances of falling asleep when 
compared to the CD and depression group. 
Although excessive daytime sleepiness has not 
been indicated in CD patients [10,20,30], Trotti et 
al. reported opposite results for their CD patients 
when compared to the control group. They 
explained that this could be attributed to the use 
of anticholinergics that can affect sleepiness 
during the day in a certain percentile of patients 
[14,32]. There is no evidence that impairment of 
sleep quality has an impact on daytime 
sleepiness [19,32]. 
Conclusion 
Sleep disturbances are frequent non-motor 
symptoms in CD, PD, and depression patients. 
According to our data, all three groups of 
patients had sleep disorders, but they differed in 
the frequency and extent of those disorders, 
with less pronounced symptoms found in CD 
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and PD patients. Symptoms of depression and 
anxiety correlate with sleep disturbances in PD 
and CD patient groups. CD patients do not 
experience daytime sleepiness problems. The 
aetiology of sleep disturbances in CD patients is 
probably related to monoamine 
neurotransmitter system impairments similar to 
those of PD patients, but to a lesser extent than 
in patients with depression. 
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